of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Stockholders approved amendments to the stock incentive plan.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition The information disclosed under the heading “Cash, Cash Equivalents and Marketable Securities as of March 31, 2026” under

Other Events Press Release Announcing Pricing of Public Offering On April 16, 2026, the Company issued a press release announcing the pricing of the Offering. A copy of the press release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Cash Runway Based on the Company’s current plans, the Company believes that its existing cash, cash equivalents and marketable securities, together with the anticipated net proceeds from the Offering, wi…

Entry into a Material Definitive Agreement On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). All…

Results of Operations and Financial Condition On March 17, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided under

Other Events On March 9, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced results of the Company’s End-of-Phase 2 meeting with the U.S. Food and Drug Administration (the “FDA”). At the meeting, the Company gained overall alignment on the plan for the remaining idiopathic pulmonary fibrosis (“IPF”)-related chronic cough development program. The Company plans to conduct two pivotal Phase 3 clinical trials and obtained agreement on the remaining Phase 1 clinical…

Chief Financial Officer and principal financial officer — David Hastings: The company hired a new Chief Financial Officer.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Other Events. On June 3, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company currently intends to use its existing cash, cash equivalents and marketable securities, plus the net proceeds from the Offering, to fund the clinical development of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonar…

Entry into a Material Definitive Agreement On June 3, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 17,400,000 shares (the “Shares”) of the Company’s co…

Other Events. On June 2, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced positive topline results from its Phase 2b CORAL clinical trial of Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (“IPF”). The primary endpoint in the Phase 2b CORAL clinical trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54…

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Results of Operations and Financial Condition On March 18, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information provided under

Other Events On March 10, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced positive topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with refractory chronic cough (“RCC”) (N=66). Haduvio met the primary endpoint with a statistically-significant reduction in the objective 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis (p<0.0001). The Phase 2a RIVER trial was a randomized, double-blind, plac…

Other Events The company updates in the Release include: Phase 2a RIVER Trial The last patient completed their final visit in the Company’s Phase 2a RIVER trial in refractory chronic cough, which was designed to enroll approximately 60 patients, at the beginning of January 2025. Topline results for the trial continue to be expected in the first quarter of 2025. Phase 2b CORAL Trial The positive outcome for the sample size re-estimation analysis for the Company’s Phase 2b CORAL trial in idiopa…

Results of Operations and Financial Condition On January 8, 2025, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release providing company updates in advance of its participation in the 14th Annual LifeSci Partners Corporate Access Event taking place in San Francisco, California from January 13 to 15, 2025, during the week of the annual J.P. Morgan Healthcare Conference (the “Release”). In the Release, the Company announced that it estimates its cash, cash eq…

Entry into a Material Definitive Agreement On December 15, 2024, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc., as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 12,500,000 shares (the “Shares”) of the Company’s common stock, par value…

Other Events. On December 16, 2024, the Company issued a press release announcing the pricing of the Offering. A copy of the press release has been filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Forward-Looking Statements Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statem…

Other Events On December 12, 2024, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced the positive outcome from the planned sample size re-estimation (the “SSRE”) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough, which requires no change to the current sample size for the trial (N=160). The trial has reached 75% of the targeted enrollment, and topline results from the full trial continue to be expected in the first half…

Other Events On December 3, 2024, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), announced positive results from the human abuse potential (“HAP”) study of oral nalbuphine. The HAP study was a randomized, double-blind, double-dummy, active and placebo controlled five-way crossover study in recreational drug users. The study’s primary endpoint was the peak effect (E max ) for “Drug Liking” (“at this moment”), assessed on a bi-polar, 100-point visual analog scale ("VAS"). The…

of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Other Events On October 21, 2024, Trevi Therapeutics, Inc. (the “Company”) announced that enrollment has been completed in the Company's Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of refractory chronic cough and the Company expects to report topline data in the first quarter of 2025. Forward-Looking Statements Statements contained in this current report on Form 8-K regarding matters that are not historical facts are "forward-looking statements" within the meaning o…